Login to Your Account



Gaining AAV Technology

Sangamo Adds Gene Therapy Assets with Ceregene Buyout

By Catherine Shaffer
Staff Writer

Tuesday, August 27, 2013
Sangamo BioSciences Inc., of Richmond, Calif., will acquire a Phase II Alzheimer’s disease gene therapy, CERE-110, plus a device for brain delivery with its acquisition of San Diego-based Ceregene Inc. Sangamo agreed to hand over 100,000 shares of its common stock, plus a payout on revenues from its products.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription